Enterolactone has stronger effects than enterodiol on ovarian cancer

• Главные авторы: Huidi Liu (Автор), Jianrui Liu (Автор), Siwen Wang (Автор), Zheng Zeng (Автор), Ting Li (Автор), Yongfang Liu (Автор), Emilio Mastriani (Автор), Qing-Hai Li (Автор), Hong-Xia Bao (Автор), Yu-Jie Zhou (Автор), Xiaoyu Wang (Автор), Sijing Hu (Автор), Shan Gao (Автор), Yingying Qi (Автор), Zhihang Shen (Автор), Hongyue Wang (Автор), Miao Yu (Автор), Tingting Gao (Автор), Randal N. Johnston (Автор), Shu-Lin Liu (Автор)
• Формат: ‌
• Опубликовано: BMC, 2017-07-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used...